These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 35171022)

  • 1. Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).
    Monforte A; Los-Arcos I; Martín-Gómez MT; Campany-Herrero D; Sacanell J; Berastegui C; Márquez-Algaba E; Sempere A; Nuvials X; Deu M; Castells L; Moreso F; Bravo C; Gavaldà J; Len O
    Microbiol Spectr; 2022 Feb; 10(1):e0178421. PubMed ID: 35171022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Invasive aspergillosis in solid organ transplantation].
    Silva JT; Torre-Cisneros J; Aguado JM
    Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients.
    Silva JT; Husain S; Aguado JM
    Transpl Int; 2023; 36():11845. PubMed ID: 38161768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Venkataramanan R; Rivosecchi RM; Tang C; Marini RV; Shields RK; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.
    Fernández-Ruiz M; Bodro M; Gutiérrez Martín I; Rodriguez-Álvarez R; Ruiz-Ruigómez M; Sabé N; López-Viñau T; Valerio M; Illaro A; Fortún J; Salto-Alejandre S; Cordero E; Fariñas MDC; Muñoz P; Vidal E; Carratalà J; Goikoetxea J; Ramos-Martínez A; Moreno A; Aguado JM;
    Transplantation; 2023 Mar; 107(3):762-773. PubMed ID: 36367924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole Prophylaxis in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
    Fontana L; Perlin DS; Zhao Y; Noble BN; Lewis JS; Strasfeld L; Hakki M
    Clin Infect Dis; 2020 Feb; 70(5):723-730. PubMed ID: 30958538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
    Maertens JA; Raad II; Marr KA; Patterson TF; Kontoyiannis DP; Cornely OA; Bow EJ; Rahav G; Neofytos D; Aoun M; Baddley JW; Giladi M; Heinz WJ; Herbrecht R; Hope W; Karthaus M; Lee DG; Lortholary O; Morrison VA; Oren I; Selleslag D; Shoham S; Thompson GR; Lee M; Maher RM; Schmitt-Hoffmann AH; Zeiher B; Ullmann AJ
    Lancet; 2016 Feb; 387(10020):760-9. PubMed ID: 26684607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world use-Isavuconazole at a large academic medical center.
    Hassouna H; Athans V; Brizendine KD
    Mycoses; 2019 Jun; 62(6):534-541. PubMed ID: 30851214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients.
    Wu X; Clancy CJ; Rivosecchi RM; Zhao W; Shields RK; Marini RV; Venkataramanan R; Nguyen MH
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
    Chitasombat MN; Kontoyiannis DP
    Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species.
    Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR
    Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
    Pfaller MA; Rhomberg PR; Castanheira M
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
    Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH
    Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.
    Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT;
    Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
    Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D
    Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients.
    Rivosecchi RM; Clancy CJ; Shields RK; Ensor CR; Shullo MA; Falcione BA; Venkataramanan R; Nguyen MH
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
    Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial.
    Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF
    J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials.
    Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isavuconazole: a new extended spectrum triazole for invasive mold diseases.
    Ananda-Rajah MR; Kontoyiannis D
    Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.